MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics

DOI Web Site Web Site Web Site 3 Citations
  • Amanda Shea
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Varsha Harish
    Groton School Groton Massachusetts 01450
  • Zainab Afzal
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Juliet Chijioke
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Habib Kedir
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Shahnoza Dusmatova
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Arpita Roy
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Malathi Ramalinga
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008
  • Brent Harris
    Department of Neurology and Pathology Georgetown University Washington District of Columbia 20057
  • Jan Blancato
    Lombardi Comprehensive Cancer Center Georgetown University Washington District of Columbia 20057
  • Mukesh Verma
    Division of Cancer Control and Population Sciences National Cancer Institute (NCI) National Institutes of Health (NIH) Rockville Maryland 20850
  • Deepak Kumar
    Division of Science and Mathematics Cancer Research Laboratory University of the District of Columbia Washington District of Columbia 20008

Description

<jats:title>Abstract</jats:title><jats:p>Glioblastoma multiforme (GBM) is the most common and lethal cancer of the adult brain, remaining incurable with a median survival time of only 15 months. In an effort to identify new targets for GBM diagnostics and therapeutics, recent studies have focused on molecular phenotyping of GBM subtypes. This has resulted in mounting interest in microRNAs (miRNAs) due to their regulatory capacities in both normal development and in pathological conditions such as cancer. miRNAs have a wide range of targets, allowing them to modulate many pathways critical to cancer progression, including proliferation, cell death, metastasis, angiogenesis, and drug resistance. This review explores our current understanding of miRNAs that are differentially modulated and pathologically involved in GBM as well as the current state of miRNA‐based therapeutics. As the role of miRNAs in GBM becomes more well understood and novel delivery methods are developed and optimized, miRNA‐based therapies could provide a critical step forward in cancer treatment.</jats:p>

Journal

Citations (3)*help

See more

Report a problem

Back to top